Aptorum Group Announces Closing of $10 Million Registered Direct Offering of Class A Ordinary Shares and Warrants
2020年2月29日 - 3:00AM
ビジネスワイヤ(英語)
Aptorum Group Limited (NASDAQ:APM) (“Aptorum Group”), a
biopharmaceutical company focused on the development of novel
therapeutics to address global unmet medical needs, today announced
the closing of a registered direct offering of 1,351,350 Class A
ordinary shares at a per share offering price of $7.40. The
investors also received accompanying warrants to purchase 1,351,350
of its Class A ordinary shares at an exercise price of $7.40 per
share. Participation in the offering includes approximately $6
million from unaffiliated institutional investors and $4 million
from Jurchen Investment Corporation, the largest shareholder of
Aptorum Group, which is wholly owned by Ian Huen, the Chief
Executive Officer and Executive Director of Aptorum Group.
A.G.P./Alliance Global Partners acted as the lead placement
agent and Maxim Group acted as co-placement agent for the
offering.
Aptorum Group received gross proceeds of $10 million from the
offering, before deducting underwriting discounts and offering
expenses. Aptorum Group intends to use the net proceeds from the
offering primarily to fund the continued research and development
of our leading therapeutic candidates (including SACT-1 and ALS-4)
into their respective clinical phases and also to expand our
discovery and development pipeline of the Smart-ACTTM orphan
diseases platform, as well as for working capital, and for general
corporate purposes. We may also use a portion of the net proceeds
to acquire or invest in technologies, products and/or businesses
that we believe will enhance the value of our Company, although
Aptorum Group has no current plans, commitments or agreements with
respect to any such transactions or acquisitions as of the date
hereof. Aptorum Group is pleased to have such US based
institutional support and as our anchor investors to support our
continued growth and expansion of our programs.
The securities described above are being offered by Aptorum
Group pursuant to a shelf registration statement on Form F-3 filed
with the Securities and Exchange Commission (SEC) dated January 6,
2020 and declared effective on January 15, 2020. A prospectus
supplement related to the offering will be, filed with the SEC and
available on the SEC’s website at http://www.sec.gov. Copies of the
prospectus supplements relating to the offering may be obtained,
when available, by contacting: Alliance Global Partners (AGP),
Prospectus Department, 590 Madison Avenue, 36th Floor, New York, NY
10022, by telephone: at (212) 624-2060, or by facsimile at
212-624-2060.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company
dedicated to developing and commercializing novel therapeutics to
tackle unmet medical needs. Aptorum Group is pursuing therapeutic
projects in orphan diseases, infectious diseases, metabolic
diseases and other disease areas.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future. As a result, the projections included
in such forward-looking statements are subject to change. Aptorum
Group assumes no obligation to update any forward-looking
statements contained in this press release as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200228005475/en/
Investors: Tel: +852 2117 6611 Email:
investor.relations@aptorumgroup.com
Media: Tel: + 852 2117 6611 Email: info@aptorumgroup.com
Aptorum (NASDAQ:APM)
過去 株価チャート
から 3 2024 まで 4 2024
Aptorum (NASDAQ:APM)
過去 株価チャート
から 4 2023 まで 4 2024